ISCO (International Stem Cell) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ISCO International Stem Cell Corp ISCO
30 GF Score
Price $0.25
GF Value $0.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is International Stem Cell Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


International Stem Cell  (OTCPK:ISCO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


International Stem Cell Cyclically Adjusted PB Ratio Related Terms


International Stem Cell Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for International Stem Cell's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

International Stem Cell Cyclically Adjusted PB Ratio Chart

International Stem Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

International Stem Cell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ISCO vs GRI, VRAX, PKTX: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, International Stem Cell's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


International Stem Cell Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, International Stem Cell's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where International Stem Cell's Cyclically Adjusted PB Ratio falls into.


ISCO
30GF Score
International Stem Cell Corp ISCO
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

International Stem Cell Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

International Stem Cell's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, International Stem Cell's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book=Book Value per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.527/330.2130*330.2130
=-0.527

Current CPI (Mar. 2026) = 330.2130.

International Stem Cell Quarterly Data

Book Value per Share CPI Adj_Book
201606 -0.309 241.018 -0.423
201609 0.116 241.428 0.159
201612 0.870 241.432 1.190
201703 0.159 243.801 0.215
201706 0.396 244.955 0.534
201709 -0.046 246.819 -0.062
201712 0.340 246.524 0.455
201803 0.264 249.554 0.349
201806 0.260 251.989 0.341
201809 0.421 252.439 0.551
201812 0.365 251.233 0.480
201903 0.422 254.202 0.548
201906 -0.159 256.143 -0.205
201909 -0.090 256.759 -0.116
201912 -0.384 256.974 -0.493
202003 -0.378 258.115 -0.484
202006 -0.479 257.797 -0.614
202009 -0.515 260.280 -0.653
202012 -0.575 260.474 -0.729
202103 -0.624 264.877 -0.778
202106 -0.539 271.696 -0.655
202109 -0.545 274.310 -0.656
202112 -0.574 278.802 -0.680
202203 -0.564 287.504 -0.648
202206 -0.553 296.311 -0.616
202209 -0.582 296.808 -0.648
202212 -0.565 296.797 -0.629
202303 -0.556 301.836 -0.608
202306 -0.481 305.109 -0.521
202309 -0.483 307.789 -0.518
202312 -0.524 306.746 -0.564
202403 -0.533 312.332 -0.564
202406 -0.502 314.175 -0.528
202409 -0.505 315.301 -0.529
202412 -0.492 315.605 -0.515
202503 -0.511 319.799 -0.528
202506 -0.487 322.561 -0.499
202509 -0.472 324.800 -0.480
202512 -0.508 324.054 -0.518
202603 -0.527 330.213 -0.527

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is International Stem Cell (ISCO) Overvalued in 2026?

Based on GuruFocus' analysis, International Stem Cell stock appears to be overvalued. The current stock price of $0.25 is trading 92.3% above its estimated GF Value™ of $0.13. GuruFocus considers International Stem Cell to be Significantly Overvalued.

Key valuation signals for ISCO:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $0.13 vs. price of $0.25 (92.3% above fair value)
  • GF Score™: 30/100 with 6 warning signs

No single metric tells the full story. See the ISCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


International Stem Cell Business Description

Address 9745 Businesspark Avenue, San Diego, CA, USA, 92131
International Stem Cell Corp is a clinical-stage biotechnology company. It is focused on therapeutic and biomedical product development with multiple long-term therapeutic opportunities. The company develops different cell types from its stem cells that may result in therapeutic products. The clinical applications of the company include neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; Liver cells, which are used to treat a variety of congenital and acquired liver diseases; and retinal cells and three-dimensional eye structures. The company operates in three segments, the therapeutic market, the biomedical market, and the anti-aging market. The Biomedical products business segment accounts for the majority of revenue.
30GF Score

Get the complete analysis for ISCO

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price
$0.13
GF Value